Medical Tech
Stock Aethlon Medical (Nasdaq: $AEMD) First Quarter Financial Results Release
and Conference Call August 13, 2025
SAN DIEGO, CA, August 5, 2025 – ( Investorideas.com
Newswire) Aethlon Medical, Inc. (Nasdaq:
AEMD), a medical therapeutic
company focused on developing products to treat cancer and life threatening
infectious diseases, today announced that it will issue financial results for
its fiscal first quarter ended June 30, 2025, at 4:15 p.m. ET on Wednesday, August
13, 2025.
Management will host a conference call on Wednesday,
August 13, 2025, at 4:30 p.m. ET to review financial results and recent
corporate developments. Following management’s formal remarks, there will be a question
and answer session.
Interested parties can register for the conference call
by navigating to https://dpregister.com/sreg/10201884/ffac7acee8. Please note that registered participants will
receive their dial-in number upon registration.
Interested parties without internet access or
unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical,
Inc. conference call.
A replay of the call will be available
approximately one hour after the end of the call through September 13, 2025.
The replay can be accessed via Aethlon Medical’s website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free
at 1-855-669-9658. The replay conference ID number is 1454680.
Paid News Dissemination of behalf of
AEMD.
Read this news, featuring AEMD in
full at https://www.investorideas.com/CO/AEMD/news/2025/08051aethlon-medical-inc-aemd-first-quarter-financial-results.asp
About the Hemopurifier®
The Aethlon Hemopurifier is an investigational
medical device designed to remove enveloped viruses and tumor-derived
extracellular vesicles (EVs) from circulation. It is used extracorporeally with
a blood pump and combines plasma separation, size exclusion, and affinity
binding using a plant lectin resin that targets mannose-rich surfaces found on
EVs and viruses. EVs released by solid tumors are believed to play a role in
metastasis and the resistance to immunotherapies and chemotherapy. Removal of
enveloped viruses and extracellular vesicles has been demonstrated in both
vitro studies and human subjects.
The Hemopurifier holds a U.S. Food and Drug
Breakthrough Device Designation for:
The treatment of individuals with advanced or
metastatic cancer unresponsive to or intolerant of standard-of-care therapy;
and the treatment of life-threatening viruses not addressed with approved
therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a
clinical-stage medical device company headquartered in San Diego, California.
Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and
infectious disease, using a novel platform designed to selectively remove
circulation pathogenic targets from biologic fluids.
For more information, visit www.AethlonMedical.com
and follow the company on LinkedIn.
Forward Looking
Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 that involve risks and uncertainties. Statements
containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect.
All forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as may be required by law,
the Company does not intend, nor does it undertake any duty, to update this
information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive
Officer and Chief Financial Officer
Aethlon Medical,
Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan
Communications, LLC
susan@sanoonan.com
More info on AEMD
at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get
News Alerts on Aethlon Medical
Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. More disclosure:
Contact management and IR of each company directly regarding specific
questions.
No comments:
Post a Comment